## Congenital malformations, deformations and chromosomal abnormalities in patients with T2DM and TUD (with obesity)
## (Comparision between matched semaglutide vs other anti–diabetes medications cohorts)

| Size/cohort | Exposure | Comparison | cases (overall risk) (Exposure) | cases (overall risk) (Comparison) | RD (95% CI) | | HR (95% CI) |
|---|---|---|---|---|---|---|---|
| 4,649 | semaglutide | insulins | 165 (3.5%) | 210 (4.5%) | −1.0% (−1.8%, −0.2%) | | 0.73 (0.59–0.89) |
| 4,652 | semaglutide | metformin | 165 (3.5%) | 160 (3.4%) | 0.1% (−0.6%, 0.9%) | | 1.03 (0.83–1.28) |
| 3,514 | semaglutide | DPP–4i | 115 (3.3%) | 118 (3.4%) | −0.1% (−0.9%, 0.8%) | | 0.96 (0.74–1.24) |
| 3,617 | semaglutide | SGLT2i | 126 (3.5%) | 124 (3.4%) | 0.1% (−0.8%, 0.9%) | | 1.00 (0.78–1.28) |
| 4,056 | semaglutide | SU | 141 (3.5%) | 133 (3.3%) | 0.2% (−0.6%, 1.0%) | | 1.04 (0.82–1.32) |
| 1,609 | semaglutide | TZD | 49 (4.0%) | 43 (2.7%) | 0.4% (−0.8%, 1.5%) | | 1.11 (0.74–1.67) |
| 4,018 | semaglutide | other GLP–1RAs | 137 (3.4%) | 119 (3.0%) | 0.5% (−0.3%, 1.2%) | | 1.14 (0.89–1.46) |

0.30 0.40   0.60 0.80 1.0   2.0   3.00
**Hazard Ratio (HR)**